← Back to Search

Suicide Prevention Interventions for Autism

N/A
Recruiting
Led By Shari Jager-Hyman, PhD
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
15-24 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up patient participants: 1-month follow-up; clinician and health system leader participants: up to 4 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing two methods to prevent suicide in autistic youth aged 12-24. One method involves creating a personalized safety plan, while the other adds ongoing support through periodic check-ins. The safety plan helps individuals recognize warning signs and use coping strategies, and the check-ins provide continuous support.

Who is the study for?
This trial is for young people aged 15-24 with autism who have had suicidal thoughts or behaviors. They must speak English and have received a safety plan tailored for autistic youth during a clinical visit. Those over 18 can consent themselves, while those under need parental consent.
What is being tested?
The study compares two suicide prevention strategies specifically designed for autistic individuals: one is the Safety Planning Intervention (SPI-A), and the other adds structured follow-up contacts to SPI-A (SPI-A+).
What are the potential side effects?
Since this trial involves non-medical interventions focused on planning and follow-ups, there are no direct medical side effects; however, discussing sensitive topics like self-harm may cause emotional discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 15 and 24 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~patient participants: 1-month follow-up; clinician and health system leader participants: up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and patient participants: 1-month follow-up; clinician and health system leader participants: up to 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feeling suicidal (finding)
Secondary study objectives
Change in access to lethal means
Change in acute care services for suicidality
Therapeutic procedure
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Safety Planning Intervention Tailored for Autistic IndividualsActive Control1 Intervention
The Safety Planning Intervention Tailored for Autistic individuals (SPI-A) is a brief collaborative intervention that results in an individually tailored plan designed to lower the short-term risk of suicide in autistic youth.
Group II: Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up ContactsActive Control1 Intervention
The Safety Planning Intervention Tailored for Autistic individuals plus structured follow-up contacts (SPI-A+) is a multi-component intervention comprised of SPI-A and structured follow-up consisting of at least 2 brief contacts.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The Safety Planning Intervention tailored for Autistic individuals (SPI-A) involves creating a personalized safety plan that includes identifying warning signs, employing internal coping strategies, utilizing social contacts for distraction, reaching out to family members or friends for support, contacting mental health professionals, and reducing access to lethal means. These mechanisms are crucial for patients with suicidal thoughts as they provide structured, immediate steps to manage crises, enhance coping skills, and ensure access to support networks, thereby reducing the risk of suicide attempts and improving overall safety.
Effectiveness of collaborative care in reducing suicidal ideation: An individual participant data meta-analysis.

Find a Location

Who is running the clinical trial?

University of North Carolina, Chapel HillLead Sponsor
1,569 Previous Clinical Trials
4,317,919 Total Patients Enrolled
16 Trials studying Autism Spectrum Disorder
2,307 Patients Enrolled for Autism Spectrum Disorder
Patient-Centered Outcomes Research InstituteOTHER
580 Previous Clinical Trials
27,103,594 Total Patients Enrolled
5 Trials studying Autism Spectrum Disorder
1,656 Patients Enrolled for Autism Spectrum Disorder
University of PennsylvaniaOTHER
2,084 Previous Clinical Trials
42,725,383 Total Patients Enrolled
15 Trials studying Autism Spectrum Disorder
2,902 Patients Enrolled for Autism Spectrum Disorder
Nationwide Children's HospitalOTHER
348 Previous Clinical Trials
5,226,145 Total Patients Enrolled
12 Trials studying Autism Spectrum Disorder
8,088 Patients Enrolled for Autism Spectrum Disorder
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.OTHER
90 Previous Clinical Trials
23,195 Total Patients Enrolled
15 Trials studying Autism Spectrum Disorder
1,867 Patients Enrolled for Autism Spectrum Disorder
Children's Hospital of PhiladelphiaOTHER
731 Previous Clinical Trials
8,471,169 Total Patients Enrolled
10 Trials studying Autism Spectrum Disorder
7,829 Patients Enrolled for Autism Spectrum Disorder
Shari Jager-Hyman, PhDPrincipal InvestigatorUniversity of Pennsylvania
1 Previous Clinical Trials
22 Total Patients Enrolled
Brenna Maddox, PhDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill
1 Previous Clinical Trials
300 Total Patients Enrolled
1 Trials studying Autism Spectrum Disorder
300 Patients Enrolled for Autism Spectrum Disorder
Danielle Roubinov, PhDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill
3 Previous Clinical Trials
268 Total Patients Enrolled

Media Library

Safety Planning Intervention tailored for Autistic Individuals Clinical Trial Eligibility Overview. Trial Name: NCT05398250 — N/A
Autism Spectrum Disorder Research Study Groups: Safety Planning Intervention Tailored for Autistic Individuals, Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts
Autism Spectrum Disorder Clinical Trial 2023: Safety Planning Intervention tailored for Autistic Individuals Highlights & Side Effects. Trial Name: NCT05398250 — N/A
Safety Planning Intervention tailored for Autistic Individuals 2023 Treatment Timeline for Medical Study. Trial Name: NCT05398250 — N/A
~694 spots leftby Sep 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top